The Impact Of Rituxan For The Treatment Of Follicular Lymphoma.
New on provides more data that treating certain lymphoma patients with an costly drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly rise life span, raising questions about whether it's worth taking. People with lymphoma who are light of maintenance treatment "really need a discussion with their oncologist," said Dr Steven T Rosen, foreman of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago. The look at involved people with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a span that refers to cancers of the immune system.
Though it can be fatal, most nation live for at least 10 years after diagnosis. There has been debate over whether people with the disease should convoy Rituxan as maintenance therapy after their initial chemotherapy. In the study, which was funded in part by F Hoffmann-La Roche, a pharmaceutical cast that sells Rituxan, roughly half of the 1019 participants took Rituxan, and the others did not. All formerly had taken the drug right after receiving chemotherapy.
In the next three years, the mull over found, people taking the drug took longer, on average, to lay open symptoms. Three-quarters of them made it to the three-year mark without progression of their illness, compared with about 58 percent of those who didn't pirate the drug. But the death rate over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.
Showing posts with label rituxan. Show all posts
Showing posts with label rituxan. Show all posts
Thursday 29 November 2018
Tuesday 29 August 2017
New Research In The Treatment Of Cancer Of Immune System
New Research In The Treatment Of Cancer Of Immune System.
New examination provides more sign that treating certain lymphoma patients with an valuable drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly gain life span, raising questions about whether it's worth taking. People with lymphoma who are making allowance for maintenance treatment "really need a discussion with their oncologist," said Dr Steven T Rosen, governor of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago. The library involved people with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a period that refers to cancers of the immune system.
Though it can be fatal, most ladies and gentlemen live for at least 10 years after diagnosis. There has been debate over whether people with the disease should escort Rituxan as maintenance therapy after their initial chemotherapy. In the study, which was funded in part by F Hoffmann-La Roche, a pharmaceutical companions that sells Rituxan, roughly half of the 1,019 participants took Rituxan, and the others did not. All in days gone by had taken the drug right after receiving chemotherapy.
In the next three years, the swat found, people taking the drug took longer, on average, to emerge symptoms. Three-quarters of them made it to the three-year mark without progression of their illness, compared with about 58 percent of those who didn't ingest the drug. But the death rate over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.
New examination provides more sign that treating certain lymphoma patients with an valuable drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly gain life span, raising questions about whether it's worth taking. People with lymphoma who are making allowance for maintenance treatment "really need a discussion with their oncologist," said Dr Steven T Rosen, governor of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago. The library involved people with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a period that refers to cancers of the immune system.
Though it can be fatal, most ladies and gentlemen live for at least 10 years after diagnosis. There has been debate over whether people with the disease should escort Rituxan as maintenance therapy after their initial chemotherapy. In the study, which was funded in part by F Hoffmann-La Roche, a pharmaceutical companions that sells Rituxan, roughly half of the 1,019 participants took Rituxan, and the others did not. All in days gone by had taken the drug right after receiving chemotherapy.
In the next three years, the swat found, people taking the drug took longer, on average, to emerge symptoms. Three-quarters of them made it to the three-year mark without progression of their illness, compared with about 58 percent of those who didn't ingest the drug. But the death rate over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.
Subscribe to:
Posts (Atom)